

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Maryvonne CHARLOT et al.

Serial No.: 09/605,054

Group Art Unit: 1617

Filed: June 28, 2000

Examiner: Alysia Berman

For: SLOW-RELEASE
MIZOLASTINE

PHARMACEUTICAL

FORMULATIONS

CONTAINING

TECH CENTER RECEIVED
02 AUG 27 PM 4:13
#13/D
9402

AMENDMENT UNDER RULE 116

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Responsive to the Office Action (Paper No. 11) of March 13, 2002, kindly amend the claims of the above-identified application as follows:

P1
29. (Amended) A sustained-release pharmaceutical dosage form according to claim 28 wherein the ratio between the mizolastine and the L-tartaric acid is 0.5.

P2
31. (Twice Amended) A coated sustained-release tablet having:

- a) a core comprising mizolastine, a fatty matrix and an organic acid;
- b) a dissolution profile which is pH independent;